Author:
Amalorpavanaden Nicholas Daniel,Oyouni Atif Abdulwahab A.,Al-Amer Osama M.,AlZamzami Waseem,Arokiyaraj Selvaraj,Hasan Mufti Ahmad,Hakami Mohammed Ageeli,Alsulami Afrah Awad Allah
Reference29 articles.
1. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma;Ascierto;J. Clin. Oncol.,2013
2. RNA splicing dysregulation and the hallmarks of cancer;Bradley;Nat. Rev. Cancer,2023
3. S100 proteins in cancer;Bresnick;Nat. Rev. Cancer,2015
4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011
5. Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth;Chen;Nat. Commun.,2018